| 1 |
Development of TNAP inhibitor, A new drug for medical treatment Aortic Stenosis |
| Small molecules |
Aortic stenosis |
TNAP |
Hit |
REDNVIA Inc. |
RS-2023-00217370 |
|
| 2 |
Development of an AI-assisted immune cell-targeted anti-Inflammatory **** lead antibody for atherosclerosis |
| Antibody |
Atherosclerosis |
**** |
Lead |
IMVASTECH |
RS-2026-25502996 |
|
| 3 |
GGT-001, Pulmonary Arterial Hypertension AAV Gene Therapy |
| Gene & Nucleic acids |
Pulmonary hypertension |
FGF12 |
Lead |
GluGene Therapeutics |
RS-2023-00217737 |
|
| 4 |
Determining the efficacy and discovery of optimal lead compounds of a novel class of diuretics, pendrin inhibitors, for treatment of congestive heart failure and chronic kidney disease |
| Small molecules |
Congestive heart failure, Chronic renal disease |
pendrin |
Lead |
Yonsei University |
HN21C0281 |
|
| 5 |
Development of a bispecific antibody targeting **** biparatopically for treating cancer-associated pulmonary embolism |
| Antibody |
Cancer-associated pulmonary embolism |
**** |
Candidate |
MabTics Co., Ltd. |
RS-2026-25502741 |
|
| 6 |
Discovery of an anticoagulant drug candidate targeting ANO6 that improves bleeding safety |
| Small molecules |
Thrombosis |
ANO6 |
Candidate |
S2Cbio Inc. |
RS-2025-02213140 |
|
| 7 |
Inhaler development with PDGFR small molecule inhibitors for pulmonary arterial hypertension |
| Small molecules |
Pulmonary hypertension |
PDGFR |
Candidate |
Voronoi, Inc |
RS-2022-00165937 |
|
| 8 |
Project Cell penetrating miRNA-based therapy for acute myocardial infarction |
| Gene & Nucleic acids |
Acute heart failure |
miRNA (miR-A, 128-3p, 34a-5p, B, 203a-3p) |
Candidate |
StemMeditech Inc. |
HN21C0741 |
|
| 9 |
GB107, Gene therapy for ischemic limb disease via new expression vector and PT1 technology |
| Gene & Nucleic acids |
Peripheral arterial disease, Diabetic peripheral neuropathy |
HGF |
Candidate |
G&P Bioscience |
HN21C0644 |
|